Role of Myo-inositol and D-chiro-inositol on Oocyte Quality

NCT ID: NCT01338844

Last Updated: 2011-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Controlled ovarian hyperstimulation with gonadotropins is an integral part of the various stimulation protocols for patients undergoing in-vitro fertilization (IVF) and other Assisted Reproductive Technologies (ART) such as intracytoplasmic sperm injection (ICSI).

The hormonal control of multiple follicular growth and maturation is a critical part of ART procedures since it maximizes the yield of embryos to be transferred, thus increasing the cumulative pregnancy rate.

Recent studies have shown the efficacy of myo-inositol (MI) supplementation as a simple and highly effective treatment in order to improve oocyte quality in patients undergoing IVF. Indeed, it was previously shown that MI follicular fluid (FF) concentration is a reliable predictor of oocyte quality. High MI concentration in the FF directly correlates with high oocyte and embryo quality.

Another stereoisomer of Inositol was successfully used into clinical practice D-chiro-inositol (DCI). In particular, DCI supplementation was used to restore ovulation in hyperglycemic PCOS patients.

In the present study we aim to compare MI versus DCI supplementation on oocyte quality of women undergoing IVF-ET

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

D-Chiro-inositol

Patients will receive 1.2g/day of D-chiro-inositol

Group Type EXPERIMENTAL

D-chito-Inositol

Intervention Type DIETARY_SUPPLEMENT

Myo-inositol

Patients will receive 4g/day of myo-inositol

Group Type ACTIVE_COMPARATOR

Myo-inositol

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Myo-inositol

Intervention Type DIETARY_SUPPLEMENT

D-chito-Inositol

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women undergoing IVF treatments
* Body mass index \<28
* FSH \<10IU/L
* Normal uterine cavity, anatomy and functions

Exclusion Criteria

* PCOS
* Stage III or IV endometriosis
* Premature ovarian failure
* Poor responder
Minimum Eligible Age

25 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Research Center for Reproductive Medicine Villa Mafalda

UNKNOWN

Sponsor Role collaborator

San Raffaele University Hospital, Italy

OTHER

Sponsor Role collaborator

AGUNCO Obstetrics and Gynecology Centre

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gianfranco Carlomagno, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

AGUNCO Obstetrics and Gynecology Centre

Vittorio Unfer, M.D.

Role: PRINCIPAL_INVESTIGATOR

AGUNCO Obstetrics and Gynecology Centre

Franco Lisi, M.D.

Role: PRINCIPAL_INVESTIGATOR

Research Center for Reproductive Medicine

Enrico Papaleo, M.D.

Role: PRINCIPAL_INVESTIGATOR

San Raffaele Hospital

Scott Roseff, MD

Role: PRINCIPAL_INVESTIGATOR

The Palm Beach Center for Reproductive Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

San Raffaele Hospital

Milan, , Italy

Site Status

Research Center for Reproductive Medicine Villa Mafalda

Roma, , Italy

Site Status

Agunco

Rome, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002 Jun;17(6):1591-6. doi: 10.1093/humrep/17.6.1591.

Reference Type BACKGROUND
PMID: 12042283 (View on PubMed)

Unfer V, Raffone E, Rizzo P, Buffo S. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol. 2011 Nov;27(11):857-61. doi: 10.3109/09513590.2011.564687. Epub 2011 Apr 5.

Reference Type BACKGROUND
PMID: 21463230 (View on PubMed)

Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci. 2010 Jun;14(6):555-61.

Reference Type BACKGROUND
PMID: 20712264 (View on PubMed)

Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009 Dec;147(2):120-3. doi: 10.1016/j.ejogrb.2009.09.008. Epub 2009 Oct 2.

Reference Type BACKGROUND
PMID: 19800728 (View on PubMed)

Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. RETRACTED: Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009 May;91(5):1750-1754. doi: 10.1016/j.fertnstert.2008.01.088. Epub 2008 May 7.

Reference Type BACKGROUND
PMID: 18462730 (View on PubMed)

Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20. doi: 10.1056/NEJM199904293401703.

Reference Type BACKGROUND
PMID: 10219066 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MI_vs_DCI_Oo_q

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.